Vaccines

Mel-Mont Medical announces the validation of its patented self-sampling technology, Mía by XytoTest®, for molecular screening using HPV-DNA and 7-Type mRNA E6/E7.

Retrieved on: 
Wednesday, August 4, 2021

KLOKKARSTUA, Norway, Aug. 4, 2021 /PRNewswire/ -- Mel-Mont Medical, a boutique medical device and technology company dedicated to improving women's health through the use of its DNA and mRNA patented self-sampling screening kit, Mia by XytoTest®, receives clinical validation as being equally effective to clinician-collected sampling.

Key Points: 
  • "Current estimates indicate that every year 569,847 women are diagnosed with cervical cancer, and 311,365 die from the disease.
  • Cervical cancer ranks as the third most frequent cancer among women in the world," according to Globocan information center on HPV and cancer.
  • The uniqueness of Ma by XytoTest empowers sexually active women to further their self-care opportunities and pre-screen for HPV-caused cancers.
  • PreTect AS, a fully ISO 13485:2016, CE/IVD certified, and FDA registered mRNA manufacturing facility based in Klokkarstua, Norway, is a wholly-owned subsidiary of Mel-Mont Medical, Inc.

University Products LLC Offers The Only Vaccine to Help Mitigate Annual Anaplasmosis Outbreaks in Cattle Herds

Retrieved on: 
Wednesday, August 4, 2021

Developed by Gene Luther, D.V.M., Ph.D., the University Products vaccine has been widely deployed since 2000 in multiple U.S. states and Puerto Rico.

Key Points: 
  • Developed by Gene Luther, D.V.M., Ph.D., the University Products vaccine has been widely deployed since 2000 in multiple U.S. states and Puerto Rico.
  • According to Healthy Farms/Health Agriculture , not all cattle infected with anaplasmosis die, but diagnosing them is important to prevent a full outbreak.
  • Treatment usually involves repeated rounds of antibiotics along with supportive care to help increase the survival rate of infected cattle.
  • "Our vaccine packet gives detailed instructions to ranchers and producers on how to help prevent a full outbreak," said vaccine creator, Dr. Luther.

Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345)

Retrieved on: 
Tuesday, August 3, 2021

The Fast Track designation for older adults underscores the urgent need for a vaccine against RSV.

Key Points: 
  • The Fast Track designation for older adults underscores the urgent need for a vaccine against RSV.
  • Respiratory syncytial virus is a common respiratory virus that generally causes cold-like symptoms.
  • Programs with Fast Track designation may benefit from early and frequent communication with the FDA, in addition to a rolling submission of the marketing application.
  • The Company previously received Fast Track designation for its COVID-19 vaccine candidate, Zika vaccine candidate (mRNA-1893), methylmalonic acidemia (MMA) (mRNA-3704) and propionic acidemia (PA) (mRNA-3927) programs.

Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study

Retrieved on: 
Tuesday, August 3, 2021

The Phase 1/2 clinical trial will evaluate the vaccines both as a primary vaccination series and as a booster following initial vaccination with Comirnaty.

Key Points: 
  • The Phase 1/2 clinical trial will evaluate the vaccines both as a primary vaccination series and as a booster following initial vaccination with Comirnaty.
  • ARCT-154 and ARCT-165 are next generation STARR mRNA vaccine candidates targeting current SARS-CoV-2 variants of concern.
  • Preclinical data demonstrated that ARCT-154 and ARCT-165 induce strong neutralizing immunogenicity in non-human primates to SARS-CoV-2 Alpha, Beta, Gamma, and Delta variants.
  • Arcturus also recently announced approval of a CTA for a Phase 1/2/3 clinical trial of ARCT-154 in Vietnam.

Replimune to Present at Two Upcoming Investor Conferences

Retrieved on: 
Monday, August 2, 2021

Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released.

Key Points: 
  • Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released.
  • Replimunes Immulytic platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes.
  • The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers.
  • Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications.For more information, please visit www.replimune.com .

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

Retrieved on: 
Friday, July 30, 2021

Dubai, United Arab Emirates, July 30, 2021 (GLOBE NEWSWIRE) -- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takedas norovirus vaccine candidate.

Key Points: 
  • Dubai, United Arab Emirates, July 30, 2021 (GLOBE NEWSWIRE) -- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takedas norovirus vaccine candidate.
  • Takeda has granted a license to HilleVax for the exclusive development and commercialization rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide outside of Japan.
  • Takeda remains committed to vaccines and this collaboration allows Takeda to focus primarily on dengue, COVID-19, pandemic influenza and Zika.
  • Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies.

Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review H2, 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021

The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" provides an overview of the Cervical Intraepithelial Neoplasia (CIN) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Cervical Intraepithelial Neoplasia (CIN).
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level
    Clinical Trials by G7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials

Two individuals fined for providing false information related to COVID-19 proof of vaccination credentials and pre-departure tests

Retrieved on: 
Friday, July 30, 2021

All travellers arriving in Canada are obligated by Canadian law to respond truthfully to all questions.

Key Points: 
  • All travellers arriving in Canada are obligated by Canadian law to respond truthfully to all questions.
  • Providing false information and/or documents to a Government of Canada official upon entry to Canada or making false statements or presenting fraudulent documents, such as vaccination credentials, is a serious offence and may result in fines and/or criminal charges.
  • Each traveller received four finesa total of $19,720 for each travellerfor providing false information related to proof of vaccination credentials and pre-departure tests, as well as, for non-compliance with the requirement to stay at a government-authorized accommodation and on-arrival testing requirements.
  • The Government of Canada continues to actively participate in discussions with the World Health Organization, the International Civil Aviation Organization and through the G7 on proof of vaccination credentials for international travel.

Research: Privilege and Politics Impact Disparity in Vaccine Rates

Retrieved on: 
Friday, July 30, 2021

It's a finding, the researchers write, that may speak to additional vaccines being more accessible to higher-income counties during vaccine rollout.

Key Points: 
  • It's a finding, the researchers write, that may speak to additional vaccines being more accessible to higher-income counties during vaccine rollout.
  • Disparity in high school graduation rates also served as a critical factor in vaccine disparity within counties.
  • Their further analysis shows that the seemingly reduced disparity is due to a lower White vaccination rate, rather than a higher Black vaccination rate.
  • States do not report vaccination rates by race consistently, making it difficult to design policy interventions and outreach strategies that can effectively address inequities in vaccination rates.

Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine

Retrieved on: 
Thursday, July 29, 2021

"Using our oral norovirus vaccine candidate, we successfully boosted the immune responses of those previously vaccinated with our platform,"said Dr. Sean Tucker, Vaxart's founder and Chief Scientific Officer.

Key Points: 
  • "Using our oral norovirus vaccine candidate, we successfully boosted the immune responses of those previously vaccinated with our platform,"said Dr. Sean Tucker, Vaxart's founder and Chief Scientific Officer.
  • Study participants were initially vaccinated withVaxart'soral norovirus vaccine in late 2019 andwerevaccinated again between February and April 2021.
  • All seven participantswhohad beenpreviously immunized with the oral norovirus vaccine elicitedasimilarbroad range ofimmune responsestonorovirusas the five subjects that had not received a prior oral vaccine dose.
  • Antibodysecreting B cell(ASC)responses to norovirus VP1 measuredseven days post-boost were no different thanthose in subjects receiving the vaccine for the first time.